382 related articles for article (PubMed ID: 35276062)
1. A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy.
Ye L; Park JJ; Peng L; Yang Q; Chow RD; Dong MB; Lam SZ; Guo J; Tang E; Zhang Y; Wang G; Dai X; Du Y; Kim HR; Cao H; Errami Y; Clark P; Bersenev A; Montgomery RR; Chen S
Cell Metab; 2022 Apr; 34(4):595-614.e14. PubMed ID: 35276062
[TBL] [Abstract][Full Text] [Related]
2. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
[TBL] [Abstract][Full Text] [Related]
3. CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies.
Wang D; Prager BC; Gimple RC; Aguilar B; Alizadeh D; Tang H; Lv D; Starr R; Brito A; Wu Q; Kim LJY; Qiu Z; Lin P; Lorenzini MH; Badie B; Forman SJ; Xie Q; Brown CE; Rich JN
Cancer Discov; 2021 May; 11(5):1192-1211. PubMed ID: 33328215
[TBL] [Abstract][Full Text] [Related]
4. A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies.
Razeghian E; Nasution MKM; Rahman HS; Gardanova ZR; Abdelbasset WK; Aravindhan S; Bokov DO; Suksatan W; Nakhaei P; Shariatzadeh S; Marofi F; Yazdanifar M; Shamlou S; Motavalli R; Khiavi FM
Stem Cell Res Ther; 2021 Jul; 12(1):428. PubMed ID: 34321099
[TBL] [Abstract][Full Text] [Related]
5. Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies.
Hu KJ; Yin ETS; Hu YX; Huang H
Curr Med Sci; 2021 Jun; 41(3):420-430. PubMed ID: 34218353
[TBL] [Abstract][Full Text] [Related]
6. Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells.
Dong MB; Wang G; Chow RD; Ye L; Zhu L; Dai X; Park JJ; Kim HR; Errami Y; Guzman CD; Zhou X; Chen KY; Renauer PA; Du Y; Shen J; Lam SZ; Zhou JJ; Lannin DR; Herbst RS; Chen S
Cell; 2019 Aug; 178(5):1189-1204.e23. PubMed ID: 31442407
[TBL] [Abstract][Full Text] [Related]
7. TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors.
Tang N; Cheng C; Zhang X; Qiao M; Li N; Mu W; Wei XF; Han W; Wang H
JCI Insight; 2020 Feb; 5(4):. PubMed ID: 31999649
[TBL] [Abstract][Full Text] [Related]
8. Strengthening the CAR-T cell therapeutic application using CRISPR/Cas9 technology.
Sadeqi Nezhad M; Yazdanifar M; Abdollahpour-Alitappeh M; Sattari A; Seifalian A; Bagheri N
Biotechnol Bioeng; 2021 Oct; 118(10):3691-3705. PubMed ID: 34241908
[TBL] [Abstract][Full Text] [Related]
9. Deletion of Cbl-b inhibits CD8
Kumar J; Kumar R; Kumar Singh A; Tsakem EL; Kathania M; Riese MJ; Theiss AL; Davila ML; Venuprasad K
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462140
[TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen receptor T cell therapy and other therapeutics for malignancies: Combination and opportunity.
Wang L; Yao R; Zhang L; Fan C; Ma L; Liu J
Int Immunopharmacol; 2019 May; 70():498-503. PubMed ID: 30875561
[TBL] [Abstract][Full Text] [Related]
11. CRISPR/Cas9-mediated TGFβRII disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells in vitro.
Alishah K; Birtel M; Masoumi E; Jafarzadeh L; Mirzaee HR; Hadjati J; Voss RH; Diken M; Asad S
J Transl Med; 2021 Nov; 19(1):482. PubMed ID: 34838059
[TBL] [Abstract][Full Text] [Related]
12. Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth.
Nakazawa T; Natsume A; Nishimura F; Morimoto T; Matsuda R; Nakamura M; Yamada S; Nakagawa I; Motoyama Y; Park YS; Tsujimura T; Wakabayashi T; Nakase H
Cells; 2020 Apr; 9(4):. PubMed ID: 32316275
[TBL] [Abstract][Full Text] [Related]
13. Current Molecular Advancements in Chimeric Antigen Receptor (CAR-T) Cells for the Treatment of Leukemia.
Bangit LEP; Derwich K
J Adolesc Young Adult Oncol; 2022 Aug; 11(4):346-351. PubMed ID: 34935501
[TBL] [Abstract][Full Text] [Related]
14. Targeting Protein Tyrosine Phosphatase 22 Does Not Enhance the Efficacy of Chimeric Antigen Receptor T Cells in Solid Tumors.
Du X; Darcy PK; Wiede F; Tiganis T
Mol Cell Biol; 2022 Mar; 42(3):e0044921. PubMed ID: 35041491
[TBL] [Abstract][Full Text] [Related]
15. Explorations of CRISPR/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy.
Naeem M; Hazafa A; Bano N; Ali R; Farooq M; Razak SIA; Lee TY; Devaraj S
Life Sci; 2023 Mar; 316():121409. PubMed ID: 36681183
[TBL] [Abstract][Full Text] [Related]
16. Long Terminal Repeat CRISPR-CAR-Coupled "Universal" T Cells Mediate Potent Anti-leukemic Effects.
Georgiadis C; Preece R; Nickolay L; Etuk A; Petrova A; Ladon D; Danyi A; Humphryes-Kirilov N; Ajetunmobi A; Kim D; Kim JS; Qasim W
Mol Ther; 2018 May; 26(5):1215-1227. PubMed ID: 29605708
[TBL] [Abstract][Full Text] [Related]
17. Biomaterials in Chimeric Antigen Receptor T-Cell Process Development.
Cardle II; Cheng EL; Jensen MC; Pun SH
Acc Chem Res; 2020 Sep; 53(9):1724-1738. PubMed ID: 32786336
[TBL] [Abstract][Full Text] [Related]
18. Production of Human CRISPR-Engineered CAR-T Cells.
Agarwal S; Wellhausen N; Levine BL; June CH
J Vis Exp; 2021 Mar; (169):. PubMed ID: 33779622
[TBL] [Abstract][Full Text] [Related]
19. CD8
Whittington KB; Prislovsky A; Beaty J; Albritton L; Radic M; Rosloniec EF
J Immunol; 2022 Jan; 208(1):16-26. PubMed ID: 34819392
[TBL] [Abstract][Full Text] [Related]
20. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]